People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Morphoceuticals, Inc. | — | Biotechnology | Series A | $13.3M | $16.4M | 2023 |
David R. Kaplan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David R. Kaplan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Jenson | 1 | 3 |
| Michael R. Levin | 1 | 2 |
| David R. Gill | 1 | 2 |
| Justin R. Briggs | 1 | 1 |
| Tamim Hamad J.J Al-Thani | 1 | 1 |
| Rosemarie R. Hunziker | 1 | 1 |
| Amy R. Kruse | 1 | 1 |
| Michael R. Hufford | 1 | 1 |
| Alexander R. Pickett | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.